{
    "pmcid": "10167778",
    "summary": "The paper titled \"Isolation and characterization of single domain antibodies from banded houndshark (Triakis scyllium) targeting SARS-CoV-2 spike RBD protein\" explores the development of single-domain antibodies (sdAbs), specifically variable new antigen receptors (VNARs), from the banded houndshark as potential therapeutic agents against SARS-CoV-2. Here is a detailed summary focusing on the insights related to nanobodies and their application in designing SARS-CoV-2 nanobody binders:\n\n### Background and Motivation\n- **COVID-19 Pandemic**: The global health crisis caused by SARS-CoV-2 has prompted the development of neutralizing antibodies, including alternative formats like sdAbs, to combat the virus.\n- **Single-Domain Antibodies (sdAbs)**: These are derived from camelid IgG2 and IgG3 or cartilaginous fish IgNARs, known as nanobodies or VNARs, respectively. They offer advantages such as small size, high stability, solubility, specificity for cryptic epitopes, low immunogenicity, ease of engineering, efficient cell penetration, and low production cost.\n- **Animal Models**: The study highlights the limited availability of animal models for VNAR discovery, with previous SARS-CoV-2 specific VNARs derived from nurse sharks, white-spotted bamboo sharks, and synthetic libraries. The banded houndshark, native to Korean coastal waters, is proposed as a new model.\n\n### Methodology\n- **Immunization and Library Construction**: A banded houndshark was immunized with recombinant SARS-CoV-2 wild-type RBD protein. RNA from the shark's spleen was used to construct a phage display immune library, resulting in a large and diverse library.\n- **Biopanning and Clone Identification**: Biopanning with the RBD antigen led to the isolation of 33 VNAR clones, with CoV2NAR-1 being the most enriched and showing high binding affinity to the RBD.\n\n### Key Findings\n- **Binding Affinity and Neutralization**: CoV2NAR-1 exhibited strong binding affinities in the nanomolar range to the wild-type RBD and variants such as Alpha, Beta, and Delta. It also demonstrated neutralizing activity against SARS-CoV-2 pseudoviruses.\n- **Physicochemical Properties**: CoV2NAR-1 was monomeric, thermally stable, and retained binding affinity after heat treatment. It showed potential for therapeutic application due to its stability and efficacy.\n- **Bivalent Formulation**: A bivalent form of CoV2NAR-1 was created, significantly improving its neutralization potency, suggesting that multivalent forms could enhance therapeutic efficacy.\n- **Epitope Mapping**: CoV2NAR-1 binds to RBD epitopes overlapping with the ACE2 binding site, which includes mutation sites like K417 and E484, indicating potential cross-reactivity with variants.\n\n### Implications and Future Directions\n- **Therapeutic Potential**: The study demonstrates the potential of VNARs from banded houndsharks as therapeutic agents against SARS-CoV-2 and possibly other pathogens.\n- **Animal Model Viability**: The banded houndshark is validated as a viable model for VNAR discovery, expanding the scope of VNAR-based research.\n- **Immunogenicity**: In silico assessments showed low immunogenicity of CoV2NAR-1, making it a promising candidate for therapeutic development.\n\n### Conclusion\nThe research highlights the successful isolation and characterization of SARS-CoV-2 RBD-specific VNARs from the banded houndshark, particularly CoV2NAR-1, which shows strong binding, neutralization, and stability properties. This study opens new avenues for using banded houndsharks in VNAR-based therapeutic and diagnostic development, emphasizing the potential of nanobodies in addressing current and future viral threats.",
    "title": "Isolation and characterization of single domain antibodies from banded houndshark (Triakis scyllium) targeting SARS-CoV-2 spike RBD protein"
}